Therapeutic Advances in Hematology : Impact Factor & More
eISSN: 2040-6215pISSN: 2040-6207
Open AccessShare this on:
Key Metrics
CiteScore 
0.7
H-Index
32
Impact Factor
< 5
SJR
Q2Hematology
SNIP
0.36
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Topics Covered on Therapeutic Advances in Hematology
Therapeutic Advances in Hematology Journal Specifications
Indexed in the following public directories
Web of Science 
Scopus 
DOAJ 
SJR
| Overview | |
| Publisher | SAGE PUBLICATIONS LTD |
| Language | English |
| Frequency | Continuous publication |
| Article Processing Charges | USD 2300 |
| Publication Time | 7 |
| Editorial Review Process | Anonymous peer review |
| General Details | |
| Language | English |
| Frequency | Continuous publication |
| Publication Start Year | 2010 |
| Publisher URL | Visit website |
| Website URL | Visit website |
| Publication Details | |
| Editorial Review Detail | |
| Information for authors | |
| Author instructions | Visit website |
| Copyright Details | Visit website |
| Deposit Policy | Sherpa/Romeo |
| License type | CC BY, CC BY-NC |
| OA statement | Visit website |
View less
Planning to publish in Therapeutic Advances in Hematology ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Therapeutic Advances in Hematology
Individualized decitabine dosing for post-HSCT maintenance in MDS and secondary AML from MDS: long-term outcomes from the PODAC trial and matched controls.
- 1 Apr 2026
- Therapeutic advances in hematology
Efgartigimod as a treatment for adults with primary immune thrombocytopenia: a plain language summary of the ADVANCE IV study.
- 1 Apr 2026
- Therapeutic advances in hematology
Prophylaxis for von Willebrand disease: Is it time for parity with established practice in hemophilia A?
- 1 Apr 2026
- Therapeutic Advances in Hematology
Neutrophil-to-lymphocyte ratio half reduction as a surrogate of molecular response in polycythemia vera treated with ropeginterferon alfa-2b
- 30 Mar 2026
- Therapeutic Advances in Hematology
Prefibrotic myelofibrosis: recent updates in diagnosis, prognostication, and management 2026
- 20 Mar 2026
- Therapeutic Advances in Hematology
Assessment of flonoltinib maleate versus ruxolitinib phosphate in intermediate- to high-risk myelofibrosis (FMF-02): study protocol for a multicenter, randomized, open-label phase IIB trial
- 19 Mar 2026
- Therapeutic Advances in Hematology
Individualized decitabine dosing for post-HSCT maintenance in MDS and secondary AML from MDS: long-term outcomes from the PODAC trial and matched controls.
- 1 Apr 2026
- Therapeutic advances in hematology
Efgartigimod as a treatment for adults with primary immune thrombocytopenia: a plain language summary of the ADVANCE IV study.
- 1 Apr 2026
- Therapeutic advances in hematology
Prophylaxis for von Willebrand disease: Is it time for parity with established practice in hemophilia A?
- 1 Apr 2026
- Therapeutic Advances in Hematology
Neutrophil-to-lymphocyte ratio half reduction as a surrogate of molecular response in polycythemia vera treated with ropeginterferon alfa-2b
- 30 Mar 2026
- Therapeutic Advances in Hematology
Prefibrotic myelofibrosis: recent updates in diagnosis, prognostication, and management 2026
- 20 Mar 2026
- Therapeutic Advances in Hematology
Assessment of flonoltinib maleate versus ruxolitinib phosphate in intermediate- to high-risk myelofibrosis (FMF-02): study protocol for a multicenter, randomized, open-label phase IIB trial
- 19 Mar 2026
- Therapeutic Advances in Hematology
FAQs on Therapeutic Advances in Hematology
How long has Therapeutic Advances in Hematology been actively publishing? 
What is the publishing frequency of Therapeutic Advances in Hematology?
How many articles did Therapeutic Advances in Hematology publish last year?
What is the eISSN & pISSN for Therapeutic Advances in Hematology?
What is Citescore for Therapeutic Advances in Hematology?
What is the H Index for Therapeutic Advances in Hematology ?
What is SNIP score for Therapeutic Advances in Hematology?
What is the SJR for Therapeutic Advances in Hematology?
Who is the publisher of Therapeutic Advances in Hematology?
